Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: Results from the CHARISMA trial

Value in Health

Volumn 12, Issue 6, 2009, Pages 872-879

  Chen, Jersey ^a   Bhatt, Deepak L ^b   Dunn, Elizabeth Schneider ^c   Shi, Chunxue ^d   Caro, J Jaime ^e   Mahoney, Elizabeth M ^f   Gabriel, Sylvie ^g   Jackson, Joseph D ^h   Topol, Eric J ⁱ   Cohen, David J ^f  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^d i3 Statprobe   (United States)

^e UNITED BIOSOURCE CORPORATION   (United States)

^f UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^g SANOFI   (France)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Aspirin; Cardiovascular disease; Clopidogrel; Cost effectiveness analysis; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART INFARCTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; OUTPATIENT CARE; PRIORITY JOURNAL; RISK REDUCTION; STATISTICAL MODEL; STROKE; SURVIVAL RATE; THROMBOSIS; TREATMENT DURATION;

AGED; ASPIRIN; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SASKATCHEWAN; SECONDARY PREVENTION; SURVIVAL ANALYSIS; TICLOPIDINE; UNITED STATES;

EID: 67651222569     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00529.x     Document Type: Article

References (31)

1. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001 345 : 494 502.
2. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001 358 : 527 33.
3. Steinhubl SR, Berger PB, Mann JT 3rd., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002 288 : 2411 20.
4. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006 354 : 1706 17.
5. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007 49 : 1982 8.
6. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006 295 : 180 9.
7. Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2004 148 : 263 8.
8. Malcolm E, Downey W, Strand LM, et al. Saskatchewan Health's linkable data bases and pharmacoepidemiology. Post Mark Surveill 1993 6 : 175 264.
9. Downey W, McNutt M, Stang MR, et al. Health Databases in Saskatchewan. In : Strom B, ed. Pharmacoepidemiology, 3rd edn. Chichester : Wiley, 2000.
10. Minnesota Department of Human Services Aging Initiative. St. Paul, MN : Minnesota Nursing Home Rates. 2002.
11. Caro JJ, Ishak KJ, Migliaccio-Walle K. Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis. Value Health 2004 7 : 627 35.
12. Caro JJ, Migliaccio-Walle K, We JJ. I. Can we predict survival following a myocardial infarction sufficiently well? ( P637). Eur Heart J 2007 28 (Suppl. 1 S89.
13. Mahoney EM, Jurkovitz CT, Chu H, et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA 2002 288 : 1851 8.
14. Mark DB, Harrington RA, Lincoff AM, et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000 101 : 366 71.
15. Weintraub WS, Mahoney EM, Lamy A, et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol 2005 45 : 838 45.
16. Weintraub WS, Zhang Z, Mahoney EM, et al. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 2005 111 : 1106 13.
17. O'Brien BJ, Briggs AH. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Stat Methods Med Res 2002 11 : 455 68.
18. United States Department of Labor - Bureau of Labor Statistics. Current Population Survey. Washington, DC : United States Department of Labor- Bureau of Labor Statistics, 2005.
19. Koopmanschap MA, Rutten FF, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995 14 : 171 89.
20. Beinart SC, Kolm P, Veledar E, et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol 2005 46 : 761 9.
21. Mahoney EM, Mehta S, Yuan Y, et al. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am Heart J 2006 151 : 219 27.
22. Kuntz KM, Tsevat J, Goldman L, et al. Cost-effectiveness of routine coronary angiography after acute myocardial infarction. Circulation 1996 94 : 957 65.
23. CAPRIE Steering Committee. A randomised, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet 1996 348 : 1329 39.
24. Cowper PA, Udayakumar K, Sketch MH Jr., et al. Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. J Am Coll Cardiol 2005 45 : 369 76.
25. Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002 346 : 1800 6.
26. Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med 2005 142 : 251 9.
27. Schleinitz MD, Weiss JP, Owens DK. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am J Med 2004 116 : 797 806.
28. De Lemos JA, McGuire DK. Aspirin, clopidogrel, or both for secondary prevention of coronary disease. N Engl J Med 2003 348 : 560 3.
29. Johannesson M, Jonsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997 336 : 332 36.
30. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007 297 : 159 68.
31. Goldberg RJ, Glatfelter K, Burbank-Schmidt E, et al. Trends in community mortality due to coronary heart disease. Am Heart J 2006 151 : 501 07.